Breaking Down Apollo Medical Holdings, Inc. (AMEH) Financial Health: Key Insights for Investors

Trading at $22.3 (last trade 02:56:59 PST) with a slight dip of -$1.18 (-0.05%), Apollo Medical Holdings presents a compelling financial story: fiscal 2024 revenue of $2.03 billion - up an astonishing 19,305.6% since 2014 - and management guiding $3.1-3.18 billion for 2025, while profitability shows an operating margin of 7.24% and net margin of 6.35%, TTM EPS of $0.98 with projected non-GAAP EPS of $1.47, and free cash flow per share of $3.19 (FCF yield 8.27%); balance-sheet dynamics include total liabilities of $840.73 million in 2024 and reported net debt near $624 million (net leverage ~2.5x on a pro forma TTM adjusted EBITDA basis) alongside robust liquidity - cash and short-term investments of ~$463 million and a current ratio of 2.35 - while valuation multiples sit at a premium P/E of 42.77x and P/S of 1.48x with analyst targets ranging $33.71-$63.00 (average $47.49) and DCF-implied intrinsic values spanning $13.94-$77.30, forcing investors to weigh acquisition-driven growth (including recent CFC asset deals and geographic expansion) and sizable upside scenarios against rising liabilities, integration and regulatory risks - read on to unpack the detailed metrics, scenario analyses and what they mean for your investment thesis

Apollo Medical Holdings, Inc. (AMEH) - Revenue Analysis

• Last trade price: 22.30 USD
• Change: -1.18 USD (-0.05%) vs. previous close
• Latest trade time: Tuesday, December 16, 02:56:59 PST

• Core revenue sources: value-based primary care contracts, Medicare Advantage risk-based arrangements, and care management fees.
• Revenue sensitivity: linked to patient panel growth, Medicare Advantage enrollment trends, and capitation rate adjustments.
• Margin pressure risks: utilization changes, medical cost trend, and investments in care-management infrastructure.

• Positive scenario: 10-20% patient-panel expansion and improved capitated rates could materially lift recurring revenue.
• Neutral scenario: flat membership with stable capitated payments keeps revenue steady but limits margin expansion.
• Negative scenario: higher-than-expected utilization or adverse rate adjustments compress margins and reduce net revenue per member.

Apollo Medical Holdings, Inc. (AMEH) - Profitability Metrics

• Annual revenue scale: $2.03 billion in 2024 vs $10.48 million in 2014 - a 19,305.6% increase.
• Projected revenue range for 2025: $3.10 billion-$3.18 billion (management guidance).
• Primary revenue drivers: healthcare management services, value-based care programs, and recently acquired patient panels/assets.
• Revenue diversification: multi-state operations reduce single-market concentration risk.
• Acquisition impact: assets from Community Family Care Medical Group IPA expected to add meaningful recurring revenue and scale.
• Volatility drivers: regulatory shifts in Medicare/Medicaid reimbursement and managed-care contracting can affect predictability.

• Margins and cash flow considerations:
  • Profitability in value-based care hinges on care management efficiency and risk-adjusted reimbursement.
  • EBITDA and net income margins can fluctuate with acquisition integration costs and start-up investments for new markets.
• Balance-sheet and capital deployment:
  • Growth-funded via operating cash flow and targeted acquisitions; capital needs rise with membership scale.
  • Prudent monitoring of working capital and A/R days is essential given rapid revenue expansion.
• Key investor considerations:
  • Watch realized savings under value-based contracts and membership growth retention rates.
  • Assess how recent acquisitions (e.g., Community Family Care Medical Group IPA assets) convert to recurring revenues and margins.
  • Monitor regulatory developments that could alter Medicaid/Medicare payment models.

Apollo Medical Holdings, Inc. (AMEH) - Debt vs. Equity Structure

Apollo Medical Holdings, Inc. (AMEH) shows a mixed profitability profile: operating efficiency has softened since 2021 while several cash- and earnings-based metrics point to underlying strength. Key figures and trends below help frame the company's ability to service debt, invest via equity, and deliver shareholder returns.

• Operating margin decline (10.83% → 7.24%) implies either higher operating costs or revenue mix shifts; monitor cost control and revenue quality.
• Robust EBIT growth (+133%) suggests operational improvements or one-time items; reconcile with margin compression to understand sustainability.
• FCF per share of $3.19 and 8.27% FCF yield provide cushioning for debt repayment, share buybacks, or reinvestment without immediate equity dilution.
• ROE at 8.10% and projected non-GAAP EPS of $1.47 indicate moderate returns with upside if margin recovery and EPS guidance materialize.

For investor context on ownership and recent market activity, see: Exploring Apollo Medical Holdings, Inc. (AMEH) Investor Profile: Who's Buying and Why?

Apollo Medical Holdings, Inc. (AMEH) - Liquidity and Solvency

• Total Liabilities (2024): $840.73 million - a 60.9% increase versus 2023, signaling rising leverage on the balance sheet.
• Net Debt (Q3 2025): ~$624 million, with a reported pro forma trailing-12-month (TTM) adjusted net leverage of 2.5x.
• Debt reduction target: Management aims to push leverage below the 3.0x range within nine months following the close of recent acquisitions.
• Equity financing: Recent capital raises and equity issuances have been used to support growth and acquisition-related funding needs.
• Interest coverage: Specific EBIT and interest expense figures were not disclosed here; coverage must be calculated from company-reported EBIT and interest expense for a precise ratio.

• Leverage Math Insight: With net debt ~$624M and reported 2.5x leverage, the implied pro forma TTM adjusted EBITDA is ~ $249.6M (624 / 2.5).
• Debt-to-Equity Inference: To derive a formal debt-to-equity ratio, use Total Debt (or Net Debt) ÷ Total Equity once the company's latest shareholders' equity balance is available.
• Interest Coverage Assessment: Compute EBIT ÷ Interest Expense using the latest income statement to evaluate whether current earnings adequately cover interest obligations.

Apollo Medical Holdings, Inc. (AMEH) - Valuation Analysis

Apollo Medical Holdings, Inc. (AMEH) presents a liquidity profile that supports near-term obligations and a solvency picture shaped by growing operating earnings and a net cash position. Key metrics and implications for valuation and investor risk tolerance are summarized below.

• Current Ratio: 2.35 - sufficient short-term assets to cover liabilities, reducing working-capital risk.
• Quick Ratio: 2.28 - strong immediate liquidity when inventory is excluded, indicating limited reliance on slow-moving assets.
• Cash & Short-Term Investments: ~$463 million as of Q3 2025 - provides a sizable liquidity buffer for operations and strategic uses.
• Free Cash Flow Conversion: Guidance of ~40%-45% of adjusted EBITDA for full-year - implies effective translation of earnings into distributable cash.
• Debt-to-Equity: Not explicitly stated; can be inferred from net debt and equity figures - rising debt exists but is mitigated by net cash and EBIT growth.
• Solvency: Despite some debt increases, the net cash position combined with rising EBIT suggests solvency risks are manageable under current operating trends.

Valuation considerations tied to these financials include the conversion rate of adjusted EBITDA to free cash flow, the sustainability of EBIT growth that underpins solvency, and the implied leverage trajectory. For investor context on ownership and share-level dynamics, see: Exploring Apollo Medical Holdings, Inc. (AMEH) Investor Profile: Who's Buying and Why?

Apollo Medical Holdings, Inc. (AMEH) - Risk Factors

Valuation sits at the center of risk assessment for Apollo Medical Holdings, Inc. (AMEH). Below are the key valuation metrics and implications investors should weigh when assessing downside and upside potential.

• Price-to-Earnings (P/E) Ratio: 42.77x - a premium multiple that signals the market is paying substantially above current earnings.
• Price-to-Sales (P/S) Ratio: 1.48x - indicates the market values roughly $1.48 for each $1 of revenue.
• Market Capitalization: ≈ $1.96 billion - positions AMEH as a mid-cap company with associated liquidity and growth expectations.

Valuation concerns for AMEH derive from multiple sources:

• High P/E (42.77x) increases the stock's vulnerability to any earnings disappointments or downward revisions.
• Wide DCF intrinsic value range ($13.94-$77.30) signals model sensitivity; small changes in growth or discount rate produce large valuation swings.
• Analyst targets spread ($33.71-$63.00) reflect divergent views on future margin improvement, patient acquisition, and reimbursement environment.
• Mid-cap market cap (~$1.96B) means liquidity and market sentiment can amplify price moves during news events or sector rotations.

Investors should cross-check valuation against operational and strategic factors, including revenue growth, margin trends, payer mix, and management execution. For additional corporate context on mission and strategic direction, see Mission Statement, Vision, & Core Values (2026) of Apollo Medical Holdings, Inc.

Apollo Medical Holdings, Inc. (AMEH) - Growth Opportunities

• Expansion of Medicare Advantage and Medicare Shared Savings Program (MSSP) contracts - scalable patient panels can drive recurring revenue and higher margins per patient.
• Care management and remote monitoring services - recurring subscription-style revenue and higher lifetime value per member.
• Geographic footprint expansion through organic growth and targeted acquisitions to increase scale and payer leverage.
• Operational leverage from population health analytics and standardization of care pathways to reduce total cost of care.

• Debt Levels: Increasing leverage-long-term debt around $215M against cash of ~$38M and modest EBITDA-raises refinancing and interest-coverage risk, especially if margin expansion stalls.
• Regulatory Changes: Revisions to Medicare Advantage payment models, value-based contracting rules, or telehealth/remote monitoring reimbursement could materially change revenue assumptions.
• Integration Risks: Recent acquisitions to scale care networks require systems, culture, and payer-contract integration. Execution delays can inflate costs and compress margins.
• Market Competition: Competing provider groups, health systems, and national MA-focused platforms can exert pricing pressure and steal market share.
• Operational Risks: Inefficiencies in care coordination, claims adjudication, or IT systems may raise operating costs and reduce expected care-cost savings.
• Economic Sensitivity: In economic downturns, elective utilization patterns, payer mix shifts, or employer-sponsored plan changes can reduce revenue or increase uncompensated care.

• High leverage magnifies downside: a modest decline in margins or delays in expected cost savings can quickly erode cash flow and increase reliance on external financing.
• Regulatory or reimbursement shocks can turn projected recurring MA/MSSP revenue growth into flat or negative trends, stressing debt covenants and valuation multiples.
• Integration missteps increase SG&A and one-time restructuring charges, turning small net losses into material cash burn if not corrected within 1-2 fiscal years.

• Membership growth and retention rates in MA and risk-based contracts.
• Risk-adjusted revenue per member and total cost of care trends versus benchmarks.
• EBITDA margins and free cash flow conversion relative to debt service needs.
• Progress on integration milestones-headcount synergy realization, IT platform consolidation, and contract transitions.
• Changes in Medicare/Medicaid rule proposals and payer reimbursement guidance.